Menu
25/09/2009
Screening For Prostate Cancer 'Remains Controversial'
There is not enough evidence to support routine prostate cancer screening.
Two papers published on bmj.com today conclude that there is insufficient evidence to support population-wide screening for prostate cancer using the prostate specific antigen (PSA) test.
The authors say that the PSA test cannot distinguish between lethal and harmless prostate cancer, leading to overdiagnosis and overtreatment of healthy men.
Prostate specific antigen (PSA) is a protein produced in the cells of the prostate gland.
It is present in small quantities in the blood of healthy men, and is often elevated in men with prostate cancer and in men with benign prostatic enlargement.
PSA screening is widely used in many countries, but it remains controversial. A recent study showed that prostate cancer deaths were lower among screened men but at a cost of considerable overdiagnosis and treatment.
So in the first study, a Swedish team of researchers set out to assess how well prostate specific antigen predicted a future prostate cancer diagnosis.
Using PSA test results from 540 men diagnosed with prostate cancer measured several years before diagnosis and from 1,034 healthy controls, they found that the PSA test did not attain the likelihood ratios (a measure used to predict disease) required for a screening test.
Only very low concentrations of PSA, less than 1ng/ml, virtually ruled out a diagnosis of prostate cancer during follow-up.
The authors conclude that additional biomarkers for early detection of prostate cancer are needed before population based screening for prostate cancer should be introduced.
In a second analysis paper, US researchers reviewed the benefits and harms of PSA screening and conclude that data on costs and benefits remain insufficient to support population based screening.
They also say that the financial and psychological costs of false positive results, overdiagnosis and overtreatment of prostate cancer need to be measured more precisely.
Finally, they believe that men should be fully informed of the benefits, risks and uncertainty associated with the PSA test before they are screened.
This view is supported in an accompanying editorial by researchers at Monash University in Australia.
Clinicians and patients are faced with many uncertainties when considering whether or not to undergo prostate screening, write Dr Dragan Ilic and Professor Sally Green.
Further research is required to develop and evaluate a valid screening test for prostate cancer, they say. Until such a test is available, a shared decision making approach to undertaking screening should be adopted.
(GK/BMcc)
Two papers published on bmj.com today conclude that there is insufficient evidence to support population-wide screening for prostate cancer using the prostate specific antigen (PSA) test.
The authors say that the PSA test cannot distinguish between lethal and harmless prostate cancer, leading to overdiagnosis and overtreatment of healthy men.
Prostate specific antigen (PSA) is a protein produced in the cells of the prostate gland.
It is present in small quantities in the blood of healthy men, and is often elevated in men with prostate cancer and in men with benign prostatic enlargement.
PSA screening is widely used in many countries, but it remains controversial. A recent study showed that prostate cancer deaths were lower among screened men but at a cost of considerable overdiagnosis and treatment.
So in the first study, a Swedish team of researchers set out to assess how well prostate specific antigen predicted a future prostate cancer diagnosis.
Using PSA test results from 540 men diagnosed with prostate cancer measured several years before diagnosis and from 1,034 healthy controls, they found that the PSA test did not attain the likelihood ratios (a measure used to predict disease) required for a screening test.
Only very low concentrations of PSA, less than 1ng/ml, virtually ruled out a diagnosis of prostate cancer during follow-up.
The authors conclude that additional biomarkers for early detection of prostate cancer are needed before population based screening for prostate cancer should be introduced.
In a second analysis paper, US researchers reviewed the benefits and harms of PSA screening and conclude that data on costs and benefits remain insufficient to support population based screening.
They also say that the financial and psychological costs of false positive results, overdiagnosis and overtreatment of prostate cancer need to be measured more precisely.
Finally, they believe that men should be fully informed of the benefits, risks and uncertainty associated with the PSA test before they are screened.
This view is supported in an accompanying editorial by researchers at Monash University in Australia.
Clinicians and patients are faced with many uncertainties when considering whether or not to undergo prostate screening, write Dr Dragan Ilic and Professor Sally Green.
Further research is required to develop and evaluate a valid screening test for prostate cancer, they say. Until such a test is available, a shared decision making approach to undertaking screening should be adopted.
(GK/BMcc)
Related UK National News Stories
Click here for the latest headlines.
16 May 2012
New Info Revises Opinion On Cancer Drug
A prostate cancer drug should be given to NHS patients, a health watchdog has said. The National Institute for Health and Clinical Excellence (Nice) revised its recommendations on the drug Abiratone after fresh information from the manufacturer, Janssen. Experts have welcomed the draft guidance.
New Info Revises Opinion On Cancer Drug
A prostate cancer drug should be given to NHS patients, a health watchdog has said. The National Institute for Health and Clinical Excellence (Nice) revised its recommendations on the drug Abiratone after fresh information from the manufacturer, Janssen. Experts have welcomed the draft guidance.
09 November 2004
Report highlights successful fight against prostate cancer
Men with prostate cancer are being seen more quickly and receiving better care according to a new report out today. The report sets out progress made following the publication of the NHS Prostate Cancer programme four years ago.
Report highlights successful fight against prostate cancer
Men with prostate cancer are being seen more quickly and receiving better care according to a new report out today. The report sets out progress made following the publication of the NHS Prostate Cancer programme four years ago.
24 May 2005
Trials for prostate cancer drugs announced
Scientists have announced that they are testing new drugs that could be used to treat advanced prostate cancer. Currently, advanced prostate cancer is treated with hormone therapy. However, this only works for a short period of time, after which there are few other options for the patient, apart from palliative care.
Trials for prostate cancer drugs announced
Scientists have announced that they are testing new drugs that could be used to treat advanced prostate cancer. Currently, advanced prostate cancer is treated with hormone therapy. However, this only works for a short period of time, after which there are few other options for the patient, apart from palliative care.
31 October 2005
Call for action on prostate cancer
The leaders of the three main political parties have issued a joint call for greater action to tackle the problem of prostate cancer. Prime Minister Tony Blair, Conservative leader Michael Howard and Liberal Democrat leader Charles Kennedy have all recorded messages of support for the Prostate Cancer Charter for Action.
Call for action on prostate cancer
The leaders of the three main political parties have issued a joint call for greater action to tackle the problem of prostate cancer. Prime Minister Tony Blair, Conservative leader Michael Howard and Liberal Democrat leader Charles Kennedy have all recorded messages of support for the Prostate Cancer Charter for Action.
24 July 2007
Cancer test kit 'could lead to 20,000 fewer deaths'
Deaths from bowel cancer could be dramatically reduced if people use a self-testing kit being sent to people in their sixties throughout the country, a cancer charity has predicted.
Cancer test kit 'could lead to 20,000 fewer deaths'
Deaths from bowel cancer could be dramatically reduced if people use a self-testing kit being sent to people in their sixties throughout the country, a cancer charity has predicted.
-
Northern Ireland WeatherToday:A showery start with outbreaks most frequent north of Lough Neagh and through the morning, before dwindling during the afternoon as the northwest breezes ease and brighter spells of weak sunshine prosper. Maximum temperature 8 °C.Tonight:A dry night, save for a few light showers around the coasts, with prolonged clear spells and light winds bringing a frosty dawn for many in central and southern parts. Minimum temperature -3 °C.
